Cargando…
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802177/ https://www.ncbi.nlm.nih.gov/pubmed/36780244 http://dx.doi.org/10.1093/crocol/otaa092 |
| _version_ | 1784861630367006720 |
|---|---|
| author | Kierkus, Jaroslaw Pesegova, Marina Klopocka, Maria Brankovic, Marija Kasai, Noriyuki Efuni, Sergey Kong, Jennifer Nakajima, Yu Jordan, Christina Matsui, Takeshi Feagan, Brian G Strout, Vincent |
| author_facet | Kierkus, Jaroslaw Pesegova, Marina Klopocka, Maria Brankovic, Marija Kasai, Noriyuki Efuni, Sergey Kong, Jennifer Nakajima, Yu Jordan, Christina Matsui, Takeshi Feagan, Brian G Strout, Vincent |
| author_sort | Kierkus, Jaroslaw |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9802177 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98021772023-02-10 Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis Kierkus, Jaroslaw Pesegova, Marina Klopocka, Maria Brankovic, Marija Kasai, Noriyuki Efuni, Sergey Kong, Jennifer Nakajima, Yu Jordan, Christina Matsui, Takeshi Feagan, Brian G Strout, Vincent Crohns Colitis 360 Corrigendum Oxford University Press 2020-12-17 /pmc/articles/PMC9802177/ /pubmed/36780244 http://dx.doi.org/10.1093/crocol/otaa092 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Kierkus, Jaroslaw Pesegova, Marina Klopocka, Maria Brankovic, Marija Kasai, Noriyuki Efuni, Sergey Kong, Jennifer Nakajima, Yu Jordan, Christina Matsui, Takeshi Feagan, Brian G Strout, Vincent Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title | Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title_full | Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title_fullStr | Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title_full_unstemmed | Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title_short | Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis |
| title_sort | corrigendum to: randomized, ascending dose, phase 2 study of khk4083, an anti-ox40 monoclonal antibody, in moderately active ulcerative colitis |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802177/ https://www.ncbi.nlm.nih.gov/pubmed/36780244 http://dx.doi.org/10.1093/crocol/otaa092 |
| work_keys_str_mv | AT kierkusjaroslaw corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT pesegovamarina corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT klopockamaria corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT brankovicmarija corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT kasainoriyuki corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT efunisergey corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT kongjennifer corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT nakajimayu corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT jordanchristina corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT matsuitakeshi corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT feaganbriang corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis AT stroutvincent corrigendumtorandomizedascendingdosephase2studyofkhk4083anantiox40monoclonalantibodyinmoderatelyactiveulcerativecolitis |